August 2011 in “Der Urologe” This review discusses the impact of various treatments for prostate cancer, noting that while 5α-reductase inhibitors reduce risk, they may not decrease and could even increase high-risk cancers; the authors highlight that recent data suggest longer screening can reduce prostate cancer mortality more effectively.
1 citations
,
May 2012 in “Aktuelle Urologie” This review discusses chemoprevention for prostate cancer and suggests that further open and unbiased investigation into various preventive compounds, including 5α-reductase inhibitors, is needed.
44 citations
,
October 2010 in “BJUI” This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.
October 2008 in “The Journal of Urology” This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.
108 citations
,
February 2008 in “The Journal of urology/The journal of urology” This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.
7 citations
,
January 2013 in “European Urology” This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.